What do studies show about Cosentyx and COVID-19 vaccine effectiveness?
Secukinumab (Cosentyx) targets interleukin-17A (IL-17A). IL-17A–blocking can change immune signaling, so researchers have looked at whether patients on Cosentyx mount adequate antibody and immune responses after COVID-19 vaccination.
Clinical guidance and studies generally indicate that patients taking IL-17 inhibitors like Cosentyx still develop vaccine-induced immune responses, but the strength of the antibody response may be lower than in healthy people (and can vary by the type of vaccine and the patient’s underlying condition). In practice, this means Cosentyx is not considered a vaccine-preventing treatment, and vaccination is still recommended while on therapy.
Do Cosentyx patients get weaker protection after vaccination?
The key point patients search for is “Will the vaccine work less?” Available evidence supports that vaccination remains effective enough to be recommended for patients on Cosentyx, though immune responses can be reduced compared with people not on immunomodulators. The degree of reduction depends on:
- which COVID-19 vaccine was given,
- how many doses/boosters the person received,
- the underlying disease being treated (for example, psoriasis vs. psoriatic arthritis vs. ankylosing spondylitis),
- time since the last Cosentyx dose and individual immune factors.
Does Cosentyx change how long vaccine protection lasts?
Most vaccine protection questions are really about duration and boosters. Evidence suggests that antibody levels may wane over time in many people, including those on immunomodulatory therapy. This is one reason booster doses are widely used, and patients on biologics like Cosentyx are typically advised to follow current booster guidance for their risk group.
Should you stop or pause Cosentyx around vaccination?
People often ask whether holding the medication improves vaccine response. Current real-world recommendations for biologics like IL-17 inhibitors generally focus on keeping treatment stable rather than routinely stopping it, because stopping therapy can risk disease flare and there is no single universal timing rule that clearly improves protection for everyone. Your prescriber may advise individualized timing based on your disease control and vaccination schedule.
What about breakthrough infections or severe COVID-19 outcomes?
Another adjacent concern is whether Cosentyx increases the risk of breakthrough COVID-19 or severe illness despite vaccination. The overall available data do not show a simple “no benefit” pattern; vaccinated patients on biologic therapy still have meaningful protection, and risk appears to depend more on factors like age, comorbidities, disease severity, and whether boosters are up to date.
Practical next steps for someone taking Cosentyx
If you’re asking because you’re about to get vaccinated (or are deciding on boosters), the most useful actions are:
- follow the COVID-19 vaccine and booster schedule recommended for your age and risk level,
- keep taking Cosentyx unless your clinician tells you otherwise,
- ask your rheumatologist/dermatologist about timing if you have a planned vaccination around the next dose.
If you share what vaccine you’re getting (and how many doses/boosters you’ve already had) and what condition you’re treating with Cosentyx, I can help translate the general findings into what questions to ask your clinician.
Sources
I don’t have the specific studies or guideline documents you want cited in your question. If you paste links or titles you’re using (or tell me your country and the vaccine type), I can summarize the exact evidence and what it says about efficacy for Cosentyx patients.